These peptides elicited robust lytic CTLs from normal donors (Figure 3), as well as breast cancer patients (Figure 7) that were effective in killing MCF-7 breast cancer cells (HLA-A*0201+, MUC1+) at high efficiency (Figure 3 and Figure 7). Here, MUC1 is linked to breast carcinoma.